

## PERFORMANCE IN DELIVERING CLINICAL RESEARCH (Q2, 2014/15)

Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Date agreed to recruit target number of patients	Trial status	Target met within the agreed time?	Comments
07/H1102/84	Sunitinib treatment of renal adjuvant cancer (S-TRAC) A randomised double blind phase 3 study of adjuvant vs placebo in subjects at high risk of recurrent RCC. Study Number: A6181109	3	No Date Agreed With Sponsor	Closed - In Follow Up	Y	Study delivered to target.
07/Q1206/53	Clinical Trial Protocol CAMN107A2303 - A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia	5	15/06/2008	Closed - In Follow Up	Y	Study delivered to time and target.
08/H1102/75	A double-blind, randomized, multicenter, placebo controlled, parallel-group study comparing the efficacy and safety of 0.5mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis	10	01/12/2011	Closed - In Follow Up	Y	Study delivered to time and target.
09/H0405/51	A Phase II Study of Dasatinib therapy in children & adolescents with PH+ leukaemia with resistance or intolerance to Imatinib.	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	
09/H0711/8	CompERA-XL: Comparison of endothelin receptor antagonist therapy in routine care	200	No Date Agreed With Sponsor	Open	N/A	7 recruited to date.
1/LO/0671	A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Closed - In Follow Up	N/A	12 patients recruited.
10/H0406/27	Randomised, Multicentre, Open-label, Phase III Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma	6	No Date Agreed With Sponsor	Open	N/A	No date agreed with sponsor.
10/H0605/58	Sub Study to study WN25203, using positron emission tomography (PET) with an amyloid tracer to assess changes in amyloid load over time in subjects with Prodromal Alzheimer's Disease	1	30/09/2012	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0605/59	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease (WN25203)	6	01/09/2013	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0711/11	Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active control Study to Determine the Efficacy and safety of Daclizumab High Yield Process (DAC HYP) versus Avonex? (Interferon ?-1a)	6	01/11/2011	Closed - In Follow Up	Y	Study delivered to time and target. 7 patients recruited within agreed date.
10/H0713/35	An International, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery	6	31/10/2014	Open	Y	Study delivered to time and target.
10/H0715/57	A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy	5	01/11/2011	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0717/68	V212 vaccination study - A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Inactivated Varicella-Zoster Virus (VZV) Vaccine	3	25/04/2013	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0801/67	Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate Cancer: Feasibility Study	15	17/07/2016	Open	N/A	Date agreed to recruit to target not yet passed.
10/H0904/49	A single arm, open-label, multicenter study evaluating the long-term safety, tolerability and efficacy of 0.5mg fingolimod (FTY720) administered orally once daily in patients with multiple sclerosis	10	01/12/2011	Closed - In Follow Up	Y	Study delivered to time and target.
10/H1306/5	A phase III open multicentre study to investigate the safety and efficacy of BPL's high purity factor X in the treatment of factor X deficient subjects undergoing surgery.	1	31/12/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/AL/0322	Phase 2 Active-controlled Double-Blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-Advanced Pancreatic Cancer	2	30/10/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/EE/0256	Multi-centre, open label, prospective, consecutive series registry database of BioPoly RS Partial Resurfacing Knee implant	10	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.

11/EM/0074	A 2-Year, multicenter, double-masked, randomised, parallel study of the safety of LUMIGAN 0.1 mg/mL compared with LUMIGAN 0.3 mg/mL in patients with glaucoma or ocular hypertension	15	30/09/2014	Open	Y	Study delivered to time and target. There are 29 patients recruited to date.
11/LO/0190	A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy	8	15/12/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/0449	A multicenter, global, randomized, double-blind study of axitinib versus placebo in patients with advanced hepatocellular carcinoma following failure of one prior antiangiogenic therapy	2	30/06/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/0537	A Multicenter, randomized, double-blind, placebo-controlled Study of the Efficacy of Natalizumab or Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis	20	29/03/2013	Closed - In Follow Up	Y	Study delivered to time and target. 33 patients recruited within agreed date.
11/LO/0551	A phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects with Solid tumors	10	31/01/2015	Open	N/A	Date agreed to recruit to target not yet passed.
11/LO/1040	A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis	2	No Date Agreed With Sponsor	Open	Y	Study delivered to target.
11/LO/1314	HICcup - HIV-1 Coreceptor tropism and disease progression adolescents with perinatally acquired infection	50	No Date Agreed With Sponsor	Closed - Follow Up Complete	Y	Study delivered to target. Target of 50 patients reached in March 2013.
11/LO/1369	A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy	1	31/08/2014	Open	N	Rare disease.
11/LO/1739	NV27779 - A phase II randomized, double-blind multicenter active-controlled parallel group study to evaluate the sustained virological response of the HCV polymerase inhibitor pro-drug RO5024048 in combination with Telaprevir and Pegasys/Copegus	5	01/09/2013	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/1904	A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX576) in asthma that is inadequately controlled with inhaled corticosteroids and long acting beta agonists	6	31/05/2013	Open	Y	Study delivered to time and target.
11/LO/2042	A Phase 2 open label biomarker study of angiotensin II type 2 receptor antagonist EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy	24	30/09/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
11/NW/0298	A multicenter, phase III, open-label, randomized study in previously untreated patients with advanced indolent non Hodgkins Lymphoma comparing GA101 (RO5072759) plus chemotherapy with rituximab plus chemotherapy followed by GA101 or rituximab	2	20/12/2013	Closed - In Follow Up	Y	Study delivered to time and target.
11/SC/0454	A phase IIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, RO 25-8310) compared to untreated control in children with HBeAg positive chronic hepatitis B	2	01/11/2014	Open	Y	Study delivered to time and target.
11/SC/0499	A UK open-label, multicentre, exploratory Phase II study of INC424 for patients with primary myelofibrosis (PMF) or post polycythaemia myelofibrosis (PPV MF) or postessential thrombocythaemia myelofibrosis (PET-MF).	1	31/08/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
11/WS/0039	A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)	1	31/03/2015	Open	Y	Study delivered to time and target.
12/EE/0005	A multicentre, double blind, randomised controlled Clinical Investigation to validate the EPS1 device as a treatment for stroke induced dysphagia. A Study of Swallowing Treatment using Electrical Pharyngeal Stimulation (STEPS Study)	6	01/01/2013	Open	N	
12/EE/0176	Randomised, phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (mtx) dosage versus maintaining the dosage in patients with severe active rheumatoid arthritis (ra)	5	01/01/2014	Open	N	To date, 2 patients recruited.
12/EE/0231	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N-Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Withdrawn	N/A	

12/EE/0400	GS-US-334-0109 ? An open label study of GS-7977 + Ribavirin for 12 weeks in subjects with chronic HCV infection who participated in prior studies evaluating GS-7977	1	No Date Agreed With Sponsor	Closed - In Follow Up	Y	Study delivered to target. Target recruitment reached - 4 patients recruited in total.
12/EE/0499	A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin	5	No Date Agreed With Sponsor	Closed - In Follow Up	Y	Study delivered to target.
12/LO/0098	A randomized, doubleblind, placebo controlled, multiple dose study to evaluate safety, tolerability, and efficacy of intravenous administration of secukinumab(AIN457) in patients with asthma not adequately controlled with inhaled corticosteroid	6	01/08/2013	Open	Y	Study delivered to time and target.
12/LO/0486	An Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of PF-05280602. A Recombinant Factor VIII Variant (813), in adult Hemophilia A and B Subjects with or without inhibitors	1	30/04/2014	Open	N	Rare disease. Study suspended by Sponsor before first patient consented at all sites.
12/LO/0858	An OpenLabel Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon a2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV)	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	This study is a treatment roll-over study so there are no recruitment targets as patients will enter depending on their treatment results in feeder study.
12/LO/0923	A Phase 3, randomized, doubleblind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castrationresistant prostate cancer	3	30/06/2015	Withdrawn	N/A	Sponsor paused screening 2 weeks after R&D approval at site, and subsequently closed recruitment prematurely at all sites.
12/LO/0980	PROTOCOL EC-FV-06: A RANDOMIZED DOUBLE-BLIND PHASE 3 TRIAL COMPARING VINTAFOLIDE (EC145) AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD/DOXIL?/CAELYX?) IN COMBINATION VERSUS PLD IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER	5	31/01/2015	Withdrawn	N/A	DSMB recommended early closure of the study.
12/LO/1173	An Open Label Phase I/II Study of GSK2110183 in Combination with Carboplatin and Paclitaxel in Subjects with PlatinumResistant Ovarian Cancer	10	31/08/2014	Open	Y	Study delivered to time and target.
12/LO/1188	A Study of HSP90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of CastrationResistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone	2	30/09/2014	Withdrawn	N	Sponsor closed study for safety reasons.
12/LO/1320	Aneurysm Treatment using the HeliFX Aortic Securement System Global Registry	5	26/11/2013	Open	N	Target of 5 patients reached within 14 months.
12/LO/1343	A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated with Human Rhinovirus Type 16	2	09/09/2014	Open	Y	Study delivered to time and target. Target reached 12 months ahead of date agreed.
12/LO/1597	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 co-administered with Ribavirin (RBV)	5	01/04/2013	Closed - In Follow Up	Y	Study delivered to time and target.
12/LO/1598	A randomized, open label study to evaluate the safety and efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 (coadministered with Ribavirin (RBV) in adults with genotype 1 chronic hepatitis C virus (HCV) infection	4	31/03/2013	Closed - In Follow Up	Y	Study delivered to time and target.
12/LO/1698	Valacyclovir in Delaying Antiretroviral Treatment Entry (VALIDATE) Short	10	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1748	A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination + Ribavirin for 12 and 24 weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV Infection	5	01/04/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/LO/1762	Left ventricular MultiSpot Pacing for CRT (iSpot)	8	24/12/2015	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1823	A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Itegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate	10	19/12/2013	Closed - In Follow Up	N	
12/LO/1861	A Randomised, Open-label, Active-controlled, Multi-centre Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation	8	30/06/2014	Closed - Follow Up Complete	N	

12/LO/1889	Openlabel,single arm extension study to the doubleblind,randomized, multicenter, placebo controlled,parallel group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	
12/LO/1981	A Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy	3	01/03/2016	Open	Y	Study delivered to time and target.
12/NW/0137	A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin	5	03/11/2017	Closed - In Follow Up	Y	Study delivered to time and target.
12/NW/0251	A multicentre, stratified, open, randomized, comparator-controlled, parallelgroup phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR	5	01/06/2015	Open	N/A	Date agreed to recruit to target not yet passed.
12/NW/0555	Randomized Phase II Study of BEZ235 vs. everolimus in Advanced Pancreatic Neuroendocrine Tumors	2	15/04/2015	Open	N/A	Date agreed to recruit to target not yet passed.
12/NW/0629	EPIC - A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.	5	18/08/2013	Closed - Follow Up Complete	N	Sponsor terminated the study.
12/NW/0682	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia	8	01/07/2013	Closed - Follow Up Complete	N	
12/NW/0711	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthionium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease	10	01/01/2014	Open	Y	Study delivered to time and target.
12/NW/0802	A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day	5	01/02/2015	Withdrawn	N	Study now abandoned.
12/SC/0031	A Phase 3 Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4n (v1) - Clinical Protocol A1444042	2	30/04/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/SC/0538	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthionium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD)	4	01/01/2014	Open	N	
12/SS/0007	A randomised Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy	4	30/01/2014	Closed - In Follow Up	N	To date, 2 patients recruited.
12/SW/0378	Effect of BivaliRudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)	6	31/10/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/WM/0341	FOURIER - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular events When AMG 145 is Used in Combination With StatinTherapy	100	01/08/2014	Open	N	
12/WS/0184	Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal AntibodyKW-0761 or Investigators Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)	3	30/06/2014	Open	Y	Study delivered to time and target.
12/YH/0178	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia	5	01/05/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/YH/0179	A Companion Trial to Study GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab as Therapy	2	19/11/2013	Closed - In Follow Up	Y	Study delivered to time and target.
12/YH/0318	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia	5	02/07/2014	Closed - In Follow Up	Y	Study delivered to time and target. There were 6 patients recruited.
13/EE/0199	An Exploratory Study of the Safety and Efficacy of BOTOX for the Treatment of Premature Ejaculation	10	01/08/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/EE/0214	A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial	1	30/09/2018	Open	Y	Study delivered to time and target.

13/EE/0257	A Phase II Clinical Trial to Study the Efficacy and Safety of a combination regimen of MK- 5172 and MK-8742 with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Genotype 2 Infection	1	28/02/2014	Closed - In Follow Up	N	
13/EE/0276	A Phase 3B Randomized, OpenLabel MultiCenter Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection	4	01/01/2014	Closed - In Follow Up	Y	Study delivered to time and target. Recruitment far exceeded target of 4 - 23 patients recruited to date.
13/EE/0364	A Randomized, Doubleblind, Multicenter Phase 2 Trial of Denosumab in Combination with Chemotherapy as Firstline Treatment of Metastatic Nonsmall Cell Lung Cancer.	12	31/05/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/EE/0365	Investigation of newly developed 1- and 2-piece convex ostomy products in subjects with ileostomy	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Withdrawn	N/A	
13/EE/0429	A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies.	6	No Date Agreed With Sponsor	Open	N/A	
13/EE/0444	Maximizing CRT Delivery by using Multipolar Coronary Sinus Lead Acuity x4	20	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/EM/0374	A doubleblind, randomized, placebocontrolled, study to demonstrate the efficacy and safety of 250 mg or 1 g A3384 administered orally twice daily for two weeks to patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	There have been 12 patients recruited.
13/EN/0348	Safety and Efficacy assessment of Monoprost? (unpreserved latanoprost) in comparison with Lumigan? 0.01 % and Lumigan? 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan? 0.01 % with ocular surfa	10	28/11/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/0006	A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects	5	31/07/2013	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/0129	A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects	6	31/05/2014	Closed - In Follow Up	N	Total of 3 patients recruited.
13/LO/0206	A phase 3 evaluation of Daclatasvir in combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatitis C Genotype 1b	4	01/11/2013	Closed - In Follow Up	N	
13/LO/0425	A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and BT-333 With and Without Ribavirin (RBV) (PEARL-IV)	5	01/05/2013	Closed - Follow Up Complete	N	UK sites only had 4 days to recruit.
13/LO/0501	A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WHO DO NOT HAVE CMV ORGAN DISEASE	1	31/03/2014	Closed - Follow Up Complete	N	Recruitment was closed by Sponsor.
13/LO/0535	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	3	26/06/2014	Closed - In Follow Up	Y	Study delivered to time and target. There were 5 patients recruited.
13/LO/0552	SinuSys Patency of Maxillary Sinus Ostia Study	6	01/06/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
13/LO/0615	A Randomized, Controlled, Open-Label, Phase 2, Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer	5	01/05/2014	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/0740	A RANDOMIZED, MULTICENTER, DOUBLE BLIND PHASE 3 STUDY OF PD 0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR S	2	30/06/2014	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/0830	Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment naive genotypes 1, 2, 3 or 4 in subjects co-infected	2	30/04/2014	Closed - Follow Up Complete	N	Site entered trial late so this has limited the genotype groups that were available to be recruited.

13/LO/0855	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphoma	4	No Date Agreed With Sponsor	Open	N	
13/LO/1050	A Multicenter, Randomized, OpenLabel, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in FirstLine Treatment of Subjects With Unresectable Hepatocellular Carcinoma	5	No Date Agreed With Sponsor	Open	N/A	
13/LO/1081	A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer	1	31/12/2018	Open	N/A	Date agreed to recruit to target not yet passed. Rare disease patient group.
13/LO/1121	A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First Line Treatment in Metastatic Non Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control	6	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1290	A Followup Study to Assess Resistance and Durability of Response to AbbVie DirectActing Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection	1	01/08/2014	Withdrawn	N	Closed by Sponsor.
13/LO/1302	A Phase IIb randomised, openlabel study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV1 infected antiretroviral therapy naive women.	4	01/08/2014	Open	Y	Study delivered to time and target. Target reached 4 months prior to agreed date.
13/LO/1323	The efficacy and safety of Ferriprox? for the treatment of transfusional iron overload in patients with sickle cell disease or other anaemias	6	No Date Agreed With Sponsor	Open	N/A	
13/LO/1332	A TwoPart Phase 1/2a, OpenLabel, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB111001 in Patients with Advanced Cancers that are Poorly Responsive to Standard Anticancer Treatment	30	No Date Agreed With Sponsor	Open	N/A	
13/LO/1352	A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE	2	No Date Agreed With Sponsor	Closed - In Follow Up	Y	Study delivered to target. Target recruitment met - 6 patients recruited.
13/LO/1557	A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival	5	31/08/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1682	Study of Maintenance Rucaparib in Relapsed High-grade Ovarian Cancer (ARIEL 3)	5	31/12/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1758	A Phase III, Randomized, PlaceboControlled, ParallelGroup, DoubleBlind Clinical Trial to Study the Efficacy and Safety of MK8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer?s Disease (Prodromal AD).	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	
13/LO/1814	A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris? (follitropin alfa and lutropin alfa) and GONAL-f? (follitropin alfa) for multifollicular development	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	
13/NE/0125	PRESTO Neo.1.C/E	8	01/08/2014	Open	N	
13/NE/0126	An exploratory, randomised, doubleblind, controlled study to assess the effect of an Amino Acid Based Formula with a synbiotic blend on gut microbiota and stool characteristics in infants.	4	30/01/2014	Open	N/A	Date agree to recruit to target not yet passed.
13/NE/0177	A phase II, randomised, double-blind, placebo-controlled study to evaluate LUM001, an apical sodium-dependent bile acid transporter inhibitor (ASBTI), in combination with ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis	3	01/03/2014	Open	N	
13/NI/0188	Syntax II - A singlearm trial to evaluate the effectiveness of PCI of de novo 3vessel disease applying the SYNTAX score II with pressure wire functional assessment and IVUS guid using an everolimuseluting stent with biodegradable abluminal coating	10	31/12/2019	Open	N/A	Date agreed to recruit to target not yet passed.
13/NW/0171	A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT-301 (Levodopa Inhalation Powder) in Parkinson?s Disease Patients With Motor Response Fluctuations (OFF Phenomena)	5	01/02/2014	Closed - Follow Up Complete	N	Eligible patients were identified but none agreed/consented to participate.
13/NW/0363	A Multicenter Openlabel Extension (OLE) Study to Assess the Longterm Safety and Efficacy of AMG 145	8	01/01/2014	Open	N	

13/NW/0464	A PlaceboControlled, Multicenter, DoubleBlind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN6556 in Subjects with Acute on Chronic Liver Failure	4	31/03/2014	Closed - Follow Up Complete	N	
13/nw/0583	A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Subjects with Type 2 Diabetes	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	
13/NW/0634	A Phase 1b, multicenter, openlabel, dose escalation study of GSK2256098 (FAK inhibitor) in combination with Trametinib (MEK inhibitor) in subjects with advanced solid tumors	5	01/10/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/NW/0778	A double-blind, randomised, placebo-controlled, Phase II study to evaluate ProCervix efficacy to clear HPV 16 and HPV 18 infection in women with normal cytology or ASCUS/LSIL	1	30/11/2014	Withdrawn	N/A	Study delivered to time and target. Closed early by sponsor as fully recruited globally.
13/NW0697	PISARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	8	14/02/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/SC/0092	A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Sisonimid (BAF312) Protocol No: CBAF312A230	6	30/04/2014	Open	N	There are 5 patients recruited, and the target of 6 is to be reached in September 2014.
13/SC/0174	A phase 2b dose-ranging, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against lysyl oxidase like molecule 2 (LOXL2) in subjects with Primary Sclerosing Cholangitis (PSC)	5	01/12/2013	Closed - Follow Up Complete	N	Study since closed by Sponsor.
13/SC/0259	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas. Gilead GS-US-313-0125	3	31/10/2014	Open	Y	Study delivered to time and target.
13/SC/0291	AN OPEN LABEL, PHASE I STUDY TO EVALUATE THE IMPACT OF SEVERE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF VEMURAFENIB IN BRAFV600 MUTATION POSITIVE CANCER PATIENTS	10	30/04/2017	Withdrawn	N	Abandoned before opening to recruitment.
13/SC/0311	A randomized, controlled, doubleblind, Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera plus cyclophosphamide, vincristine, prednisone	3	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/SC/0348	A randomized, OpenLabel, Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib	6	01/10/2014	Open	N/A	Rare disease. Date agreed to recruit to target not yet passed.
13/SC/0360	A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa 2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C	4	21/10/2013	Closed - In Follow Up	Y	Study delivered to time and target.
13/SC/0383	A Two Part, Randomized Clinical Trial to Study Biomarkers of MK8237 (SCH 900237) Treatment in Subjects with House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis	20	31/01/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/SC/0559	Telotristat Etiprate for Carcinoid Syndrome Therapy - TELECAST: A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome	2	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/SC/0589	TURBO - Optimisation of Onpulse technology for patients with post surgical or vascular oedema	10	30/07/2014	Open	N	
13/SW/0124	A PERFORMANCE EVALUATION STUDY OF UROSENS? MCM5-ELISA FOR THE DETECTION OF PROSTATE CANCER IN PATIENTS WITH KNOWN DISEASE AND IN THOSE PRESENTING WITH RAISED SERUM PROSTATE-SPECIFIC ANTIGEN AND/OR ABNORMAL PROSTATE GLAND MORPHOLOGY	19	28/02/2014	Open	Y	Study delivered to target. No date agreed. There 13 recruited to date.
13/WA/0064	A PERFORMANCE EVALUATION STUDY OF UROSENS?? MCM5 ELISA TEST IN THE DIAGNOSIS OF BLADDER CANCER IN PATIENTS PRESENTING WITH HAEMATURIA AND LOWER URINARY TRACT SYMPTOMS WITH SUSPICION OF MALIGNANCY	250	15/01/2014	Open	N	

13/WA/0178	A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable	5	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/WA/0328	Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer	2	31/07/2015	Open	Y	Study delivered to time and target.
13/WS/0172	Rucaparib in Platinum-Sensitive Relapsed High Grade Ovarian Cancer	8	13/12/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/WS/0282	ILLUMENATE - Prospective, single-arm, global multi-center study to evaluate treatment of obstructive superficial femoral artery and/or popliteal lesions with a novel paclitaxel coated percutaneous angioplasty balloon.	10	01/01/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/YH/0174	A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial Spondyloarthritis	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Withdrawn	N/A	Site withdrew from trial.
14/EM/0186	PERSIST-2 - A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis.	2	14/08/2018	In set up	N/A	Date agreed to recruit to target not yet passed.
14/LO/0362	Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension	3	28/08/2015	Open	N/A	Date agreed to recruit to target not yet passed.
14/LO/0665	A Phase III OpenLabel Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK5172/ MK8742 in TreatmentNaive Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy.	4	No Date Agreed With Sponsor	Closed - In Follow Up	Y	Study delivered to target.
14/LO/0717	Bosutinib Vs Imatinib in Newly Diagnosed CML ( AVILLION)	2	12/05/2020	Open	N/A	Date agreed to recruit to target not yet passed.
14/LO/0882	GO28915 MPDL3280A or Docetaxel in Patients with NSCLC (OAK)	4	01/06/2015	Open	N/A	Date agreed to recruit to target not yet passed.
14/LO/1053	A Phase 3 Randomised double blind Active study Evaluating Memelotinib vs Ruxolitinib in subjects with primary Myelofibrosis (PMF) or Post-poly cythemia Vera or Post-essential Thrombocythemia Myelofibrosis ( Post-PV/ET MF)	2	01/12/2017	In set up	N/A	Date agreed to recruit to target not yet passed.